A detailed history of Ensign Peak Advisors, Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 28,264 shares of ITCI stock, worth $2.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,264
Previous 41,637 32.12%
Holding current value
$2.44 Million
Previous $2.85 Million 27.53%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $909,230 - $1.08 Million
-13,373 Reduced 32.12%
28,264 $2.07 Million
Q2 2024

Aug 13, 2024

SELL
$64.76 - $79.84 $6.48 Million - $7.98 Million
-100,000 Reduced 70.6%
41,637 $2.85 Million
Q1 2024

May 14, 2024

BUY
$64.37 - $75.65 $6.35 Million - $7.46 Million
98,574 Added 228.91%
141,637 $9.8 Million
Q3 2023

Nov 13, 2023

SELL
$52.09 - $64.1 $42,974 - $52,882
-825 Reduced 1.88%
43,063 $2.24 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $742,322 - $965,866
16,948 Added 62.91%
43,888 $2.38 Million
Q4 2022

Feb 13, 2023

BUY
$44.07 - $54.45 $114,582 - $141,570
2,600 Added 10.68%
26,940 $1.43 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $4.32 Million - $6.07 Million
-101,153 Reduced 80.6%
24,340 $1.13 Million
Q2 2022

Aug 12, 2022

SELL
$43.0 - $65.64 $389,580 - $594,698
-9,060 Reduced 6.73%
125,493 $7.16 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $434,895 - $697,022
11,226 Added 9.1%
134,553 $8.23 Million
Q4 2021

Feb 11, 2022

BUY
$35.2 - $53.42 $1.38 Million - $2.09 Million
39,067 Added 46.36%
123,327 $6.46 Million
Q3 2021

Nov 12, 2021

BUY
$28.72 - $42.49 $357,937 - $529,552
12,463 Added 17.36%
84,260 $3.14 Million
Q4 2020

Feb 12, 2021

BUY
$23.34 - $32.22 $1.02 Million - $1.41 Million
43,806 Added 156.5%
71,797 $2.28 Million
Q3 2020

Nov 12, 2020

BUY
$17.61 - $31.86 $492,921 - $891,793
27,991 New
27,991 $718,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.16B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.